Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy.
The maternal and fetal endocrine effects of the maternal administration of the anti-progestin mifepristone in mid-pregnancy have been investigated. Mifepristone and the metabolite RU 42,633 were detected in the fetal circulation and in the amniotic fluid 4, 24 and 48 h after oral ingestion. Maximum fetal plasma concentrations of mifepristone occurred 4 h after treatment indicating rapid placental transfer of the drug. No significant changes in progesterone, cortisol, oestradiol or aldosterone concentrations were detected in the maternal circulation after mifepristone treatment. No significant changes occurred in the fetal progesterone, oestradiol or cortisol concentrations, but a significant increase in fetal aldosterone occurred 4 and 24 h after treatment. The significance of these results is discussed in relation to the possible therapeutic uses of mifepristone for inducing labour.
Hill
N C
NC
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Headington, UK.
Selinger
M
M
Ferguson
J
J
MacKenzie
I Z
IZ
D000028:Abortion, Induced / Q000379:methods*; D000328:Adult; D005260:Female; D005312:Fetal Blood / Q000378:metabolism*; D006801:Humans; D008431:Maternal-Fetal Exchange / Q000502:physiology*; D015735:Mifepristone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second / Q000097:blood; D013256:Steroids / Q000097:blood*
D013256:Steroids; C060995:Ru 42633; D015735:Mifepristone